His primary areas of investigation include Immunology, Internal medicine, Acquired immunodeficiency syndrome, Cohort study and Viral load. His Immunology research incorporates elements of Odds ratio, Incidence and Hazard ratio. His Internal medicine research incorporates themes from Gastroenterology, Surgery and Ritonavir.
His studies in Acquired immunodeficiency syndrome integrate themes in fields like Viral disease, Pharmacotherapy and Epidemiology. His Cohort study study combines topics in areas such as Prospective cohort study, Survival analysis, Pediatrics and Cohort. Hansjakob Furrer combines subjects such as Developed country, Environmental health, Cellular immunity, Program evaluation and Antiretroviral therapy with his study of Viral load.
Hansjakob Furrer mostly deals with Internal medicine, Immunology, Cohort study, Acquired immunodeficiency syndrome and Viral load. His Internal medicine study frequently draws connections between adjacent fields such as Surgery. His research in Immunology intersects with topics in Tuberculosis and Virology.
His study focuses on the intersection of Cohort study and fields such as Odds ratio with connections in the field of Logistic regression. The study incorporates disciplines such as Pharmacotherapy and Risk factor in addition to Acquired immunodeficiency syndrome. His study in Viral load is interdisciplinary in nature, drawing from both Gastroenterology and Regimen.
The scientist’s investigation covers issues in Internal medicine, Cohort study, Prospective cohort study, Viral load and Odds ratio. Within one scientific family, Hansjakob Furrer focuses on topics pertaining to Randomized controlled trial under Cohort study, and may sometimes address concerns connected to Emergency medicine, Linear model and Marginal structural model. His work deals with themes such as Regimen, Acquired immunodeficiency syndrome, Coinfection, Seroconversion and Pediatrics, which intersect with Prospective cohort study.
His Viral load study necessitates a more in-depth grasp of Immunology. Particularly relevant to T lymphocyte is his body of work in Immunology. His Odds ratio research is multidisciplinary, incorporating elements of Overweight, Men who have sex with men and Quartile, Confidence interval.
Hansjakob Furrer mainly focuses on Prospective cohort study, Internal medicine, Cohort study, Cohort and Pediatrics. His Prospective cohort study research integrates issues from Acquired immunodeficiency syndrome, Viral load and Hazard ratio. His Internal medicine study incorporates themes from Virological response, Surgery, Immunology and Hepatitis C virus.
Hansjakob Furrer interconnects Liver cancer and Hepatocellular carcinoma in the investigation of issues within Immunology. His Cohort study study integrates concerns from other disciplines, such as Dolutegravir, Discontinuation and Confidence interval. The Pediatrics study combines topics in areas such as Odds ratio, Relative risk, Randomized controlled trial, Reverse-transcriptase inhibitor and Drug resistance.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Genetic Variation in IL28B Is Associated With Chronic Hepatitis C and Treatment Failure: A Genome-Wide Association Study
Andri Rauch;Zoltán Kutalik;Zoltán Kutalik;Patrick Descombes;Tao Cai.
Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study.
Gilbert Greub;Bruno Ledergerber;M. Battegay;P. Grob.
The Lancet (2000)
Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients : a prospective cohort study
Bruno Ledergerber;Matthias Egger;Milos Opravil;Amalio Telenti.
The Lancet (1999)
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study.
Jacques Fellay;Catia Marzolini;Emma R. Meaden;David J. Back.
The Lancet (2002)
Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis.
Monika Müller;Simon Wandel;Robert Colebunders;Suzanna Attia.
Lancet Infectious Diseases (2010)
AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study.
Bruno Ledergerber;M. Egger;V. Erard;R. Weber.
Morbidity and Aging in HIV-Infected Persons: The Swiss HIV Cohort Study
Barbara Hasse;Bruno Ledergerber;Hansjakob Furrer;Manuel Battegay.
Clinical Infectious Diseases (2011)
Mycobacterium avium subspecies paratuberculosis and Crohn's disease: a systematic review and meta-analysis.
Martin Feller;Karin Huwiler;Roger Stephan;Ekkehardt Altpeter.
Lancet Infectious Diseases (2007)
CD4 T-Lymphocyte Recovery in Individuals With Advanced HIV-1 Infection Receiving Potent Antiretroviral Therapy for 4 Years: The Swiss HIV Cohort Study
Gilbert R. Kaufmann;Luc Perrin;Guiseppe Pantaleo;Milos Opravil.
JAMA Internal Medicine (2003)
Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study
Jacques Fellay;Bruno Ledergerber;Enos Bernasconi;Hansjakob Furrer.
The Lancet (2001)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: